A new study conducted by researchers at Children's Hospital & Research Center Oakland shows that a century-old drug, methylene blue, may be able to slow or even cure Alzheimer's and Parkinson's disease. Used at a very low concentration – about the equivalent of a few raindrops in four Olympic-sized swimming pools of water – the drug slows cellular aging and enhances mitochondrial function, potentially allowing those with the diseases to live longer, healthier lives.
Potential Alzheimer's, Parkinson's Cure
Found In Century-old DrugA paper on the methylene blue study, conducted by Hani Atamna, PhD, and a his team at Children's, was published in the March 2008 issue of the Federation of American Societies for Experimental Biology (FASEB) Journal. Dr. Atamna's research found that methylene blue can prevent or slow the decline of mitochondrial function, specifically an important enzyme called complex IV. Because mitochondria are the principal suppliers of energy to all animal and human cells, their healthy function is critical.
"The results are very encouraging," said Dr. Atamna. "We'd eventually like to try to prevent the physical and cognitive decline associated with aging, with a focus on people with Alzheimer's disease. One of the key aspects of Alzheimer's disease is mitochondrial dysfunction, specifically complex IV dysfunction, which methylene blue improves. Our findings indicate that methylene blue, by enhancing mitochondrial function, expands the mitochondrial reserve of the brain. Adequate mitochondrial reserve is essential for preventing age-related disorders such as Alzheimer's disease."
Also impressed is one of Dr. Atamna's co-authors, Bruce Ames, PhD, a senior scientist at Children's and world-renowned expert in nutrition and aging. "What we potentially have is a wonder drug." said Dr. Ames. "To find that such a common and inexpensive drug can be used to increase and prolong the quality of life by treating such serious diseases is truly exciting."
Methylene blue, first discovered in 1891, is now used to treat methemoglobinemia, a blood disorder. But because high concentrations of methylene blue were known to damage the brain, no one thought to experiment with low concentrations. Also, drugs such as methylene blue do not easily reach the brain.
Dr. Atamna's research is the first to show that low concentrations of the drug have the ability to slow cellular aging in cultured cells in the laboratory and in live mice. He believes methylene blue has the potential to become another commonplace low-cost treatment like aspirin, prescribed as a blood thinner for people with heart disorders.
Dr. Atamna's research, funded by the Bruce and Giovanna Ames Foundation, was conducted at Children's research institute and will continue when Dr. Atamna assumes a position as a professor of Neuroscience at The Commonwealth Medical College in Pennsylvania.
Journal reference:
Atamna et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. The FASEB Journal, 2007; 22 (3): 703 DOI: 10.1096/fj.07-9610com
Smart mice
Working memory
Neurotechnology
Viagra for the brain?
Calcineurin-inhibition
Pyrrolidone derivatives
Growing new brain cells
Why is it hard to forget?
Exercise and neurogenesis
Smart drugs and aging brains
Scepticism about smart drugs
Mood and cognitive performance
Antidepressants and new brain cells
Do smart pigeons outperform dumb kids?
Refs
and further readingHOME
HedWeb
Future Opioids
BLTC Research
Superhappiness?
The Good Drug Guide
Paradise-Engineering
The Abolitionist Project
MDMA: Utopian Pharmacology
